Safety Evaluation Of Vaccines In Pregnant Women And Infants


  • Dr.R.Saravanan , Farahan Subahan



Introduction: Immunizing pregnant women is a straightforward and highly efficient strategy for preventing the spread of preventable diseases to both mother and child. Pregnancy-related immune alterations have been linked to an increased risk of severe outcomes from a variety of infectious illnesses. The mother and the unborn child may both benefit from vaccinations given to pregnant women to avoid vaccine-preventable diseases.

Methods: This review draws from articles found through a focused search of the literature on the immunological aspects of infectious illnesses affecting pregnant women, foetuses, and newborns, paying special attention to WHO recommendations.

Results: Pregnant women who receive vaccinations are shielded from a variety of serious infectious illnesses throughout their pregnancy. Influenza, tetanus, and pertussis vaccination with inactivated vaccines is efficient, secure, and well-tolerated. The WHO recommends tetanus vaccination for women who are expecting or who are of childbearing age. An inactivated quadrivalent influenza vaccination should be given to all pregnant women beginning in the second trimester. After receiving an acellular pertussis vaccine, the acquired protection lasts just a brief period of time. Future research is required to fill up significant information gaps, despite mounting evidence in favour of immunisation during pregnancy. In order to maximise safety for both the mother and the child, this joint consensus document reviews the existing literature on vaccination during pregnancy, identifies knowledge gaps, and establishes priorities for next research endeavours.

Conclusion: Until infants can develop their own adaptive immunity, mother vaccination is a safe and efficient method of providing passive immune protection against potentially fatal illnesses.



2022-12-31 — Updated on 2022-12-31




How to Cite

Safety Evaluation Of Vaccines In Pregnant Women And Infants. (2022). Journal of Pharmaceutical Negative Results, 4987-4997.